CSPC PHARMACEUTICAL: Stay invested!

Free Issue No. 08 of 22.04.2021
Let me say this in advance: In many emerging markets, the population expects high-quality access to healthcare services. In China, this process has been underway for some time and is linked to great growth potential. The pharmaceutical and biotech company CSPC PHARMACEUTICAL is also doing very well. Gross profit increased by +12.8% in 2020; net by as much as +17.4%. With its strong and professional market development capabilities, a comprehensive management system, an excellent corporate culture and, above all, a sustained R&D (research and development) innovation capability, the Group has become a leading company that ranks among the industry benchmarks. Once again, key products such as NBP, Duomeisu, Jinyouli and Keaili achieved remarkable sales. More than 150 medical research projects support market penetration and ensure continuous growth. A high level of academic support for personnel forms the basis for a bright future. An extensive product range in the generics sector also provides pleasing economies of scale. Clinical development of products and indications made many advances in 2020, with 17 products approved as drugs, 14 products approved for clinical trials, and 24 products approved for generic consistency evaluation.

Looking ahead, the CSPC Group is focusing on the following three aspects: 1. strengthening the ability to further develop the commercialized market, with industry-leading market share for each core product in the sales pipeline; 2. further enhancing the innovation capability and efficiency of R&D; 3. accelerating the internationalization process. Expand revenue streams with international partners. We sense a lot of momentum with high quality demands. Therefore definitely stay invested! Target price: HKD 19!

CSPC PARMACEUTICAL is listed on the Hong Kong Stock Exchange under the symbol 1093, the security number is 1'604'915, last price approx. HKD 9.75.